Home
  • Our Company
    • Biopharmaceutical Acceleration Model®
    • Dynamic Assembly®
    • Kinetic™
    • Syneos One®
    • The Trusted Process®
    • Our Leadership
    • Our Vision, Mission and Values
    • Resource Library
    • Events
    • Awards
    • Site Relationships
    • Our Office Locations
  • Solutions
    • Clinical Development
      • Full Service
        • Decentralized Solutions
        • Bioanalytical Solutions
        • Early Phase
        • Phase II - III
        • Phase IIIb - IV
        • Real World and Late Phase
        • Medical Device and Diagnostics
      • FSP 360
        • Biostatistics and Statistical Programming
        • Clinical Data Management
        • Clinical Development Services Project Management
        • Clinical Monitoring
        • Drug Safety and Pharmacovigilance
        • Investigator Management Solutions
        • Medical Writing and Communications
        • Rater Training
        • Site Start Up
        • Site and Patient Access
        • Trial Master File Operations
    • Commercialization
      • Advertising
      • AnswerSuite
      • Behavioral Insights
      • Brand Commercialization
      • Brand Naming and Development
      • Clinical Field Teams
      • Commercial Model of the Future
      • Commercial Recruiting Solutions
      • Communications
      • Deployment Solutions
      • Digital and Social Media
      • Full-Service Commercial
      • Health Economics and Outcomes Research
      • Medical Affairs Transformation
      • Medical Communications
      • Policy and Advocacy
      • Portfolio Strategy
      • Public Relations
      • REMS and Risk Management (PMO)
      • Reputation and Risk Management
      • Selling Solutions
      • Training and Learning Solutions
      • Value and Access
    • Consulting
      • Commercial Advisory Group
        • Portfolio Strategy and Transactions
        • Health Economics and Outcomes Research
        • Product and Franchise Strategy
        • Value and Access
        • Customer and Digital Engagement
      • Scientific and Medical Affairs Advisory Group
        • Medical Affairs
        • Quality and Compliance
        • Regulatory
      • Risk and Program Management Advisory Group
        • REMS and Risk Management (PMO)
      • R&D Advisory Group
        • Research and Development
    • Syneos One®
  • Therapeutic Expertise
    • Therapeutic Areas
      • Cardiovascular
      • Central Nervous System
        • CNS Analgesia
        • CNS Clinical Surveillance Team
        • CNS Neurology
        • CNS Psychiatry
      • Endocrine and Metabolic
      • Gastroenterology
      • Immunology and Inflammation
      • Infectious Disease and Vaccines
      • Ophthalmology
      • Respiratory
      • Women's Health
      • Oncology and Hematology
        • Targeted Therapies
        • Novel and Emerging Therapies
        • Immuno-Oncology
    • Cross-Functional Solutions
      • Biosimilars
      • Cell and Gene Therapy
      • Patient Voice
      • Pediatrics
      • Rare Diseases
    • Our Experience Hub
  • Insights Hub
  • Careers
  • インサイト ハブ
  • 中途採用
  • 新卒採用 (日本)
  • News
    • In The News
    • Press Releases
    • Press Kit
  • Investors
  • Investigators
  • Transparency
  • Suppliers
    • Supplier Code of Conduct
    • Standard Contractual Clauses for Suppliers
    • Supplier Diversity and Inclusion
    • Supplier Terms and Conditions
  • Contact
  • English
  • Français Canadien
  • 日本語

Search form

Home Insights Hub The 2021 Health Trends Series China: The New Pace Car of Change
Trends

China: The New Pace Car of Change

March 25, 2021
Content 

What was an untapped market mere years ago is now surging. The pharmaceutical and biotech market in China is experiencing the most dramatic growth in the world, with in-region innovation, increased approvals of novel drugs and maturing research and development capabilities. One key reason why: differences in regulations between the Western World and China allow researchers there to more quickly understand how a treatment is working and make modifications on shorter time frames. That’s making China a center for gene therapy and CAR-T medical discovery and clinical trials. Biotechs within China and pharma leaders around the world are doing research at scale in the region, effectively working with CFDA to get protocols approved within a year. There are complexities, of course, including building specialty labs in the region and training new trial sites. But, the benefits to patients are outsized: access to novel oncology medications before the rest of world.

Image or Video 

China - The New Pace Car of Change.png

China - The New Pace Car of Change
Critical Question

As we enter 2021, it’s a footrace. Who will move fastest and get the most penetration: local biotech, out-of-region biotech, or large pharma who have scaled up investment in China for a decade?

Did you know...

Columns 
Content 
Image or Video 

$12 Billion - China The New Pace Car of Change.png

$12 Billion - China  The New Pace Car of Change

$12 Billion: Venture capital investment may have slowed overall in the face of the pandemic, but not in Chinese biotech. The first half of 2020 saw 95 biotech deals, worth $12 billion, an unprecedented amount of activity.

— Bioworld, 2020

Content 
Image or Video 

54% - China The New Pace Car of Change.png

54% - China  The New Pace Car of Change

54%: China leads the world in the number of active CAR-T trials with 54.2%. The U.S. is second with 38.5%, and the next largest trial centers come in with single digits (UK, 4.5%; France, 4.1%; Belgium, 3.6%).

— DRG, 2020

 

Download a PDF of This Content Below

The 2021 Health Trends Series
Combating Complexity
Acute Uncertainty
Enabled 
Download
Previous Next

Fill out the form below to download your requested Insights Hub Article.

*Required fields

By submitting this form, you agree to our Terms & Conditions and Privacy Policy of our website. You can withdraw your consent at any time. If you have any questions, please Contact Us.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chapters

Chapter:
13
Privacy and Convenience
Chapter:
14
Retention Reboot
Chapter:
15
Acute Uncertainty
Chapter:
16
Combating Complexity
Chapter:
17
China: The New Pace Car of Change
Chapter:
18
Forming the Future Field

Pages

  • « first
  • ‹ previous
  • 1
  • 2
  • 3
  • 4
  • next ›
  • last »
Branded Logo
Contact Us Today Share

Related Content

The 2021 Health Trends Series
July 1, 2021
Combating Complexity
March 18, 2021
Acute Uncertainty
March 11, 2021
Interested in Syneos Health?
Get In Touch
Connect
  • LinkedInLinkedIn
  • TwitterTwitter
  • FacebookFacebook
  • InstagramInstagram

Syneos Health

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically blending clinical development, medical affairs and commercial capabilities to address modern market realities. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. We support a diverse, equitable and inclusive culture. Contact Us

Our Headquarters
Corporate Headquarters
  • 1030 Sync Street
  • Morrisville, NC 27560
  •  
  • Phone: +1 919 876 9300
  • Fax: +1 919 876 9360
  • Toll-Free: +1 866 462 7373
Menu
  • Solutions
  • Therapeutic Expertise
  • Brand Directory
  • 労働者派遣法に基づく情報公開
  • Careers
  • Study Participants
  • Media
  • Business Ethics Helpline
  • Events
  • Transparency
© 2022 Syneos Health. All Rights Reserved.
  • Terms Of Use
  • Privacy Notice
  • Privacy Shield
  • Online Tracking Opt-Out